Afimoxifene
99%
- Product Code: 61204
Alias:
(E/Z)-4-Hydroxytamoxifen
CAS:
68392-35-8
Properties:
Racemate of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen. the
| Molecular Weight: | 387.51 g./mol | Molecular Formula: | C₂₆H₂₉NO₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Afimoxifene is primarily used in the treatment of breast cancer, particularly in cases where the cancer is estrogen receptor-positive. It works by blocking the effects of estrogen on breast tissue, thereby inhibiting the growth of cancer cells that rely on estrogen to proliferate. This makes it a valuable option for both the prevention and treatment of breast cancer in postmenopausal women.
In addition to its anticancer properties, afimoxifene is also being investigated for its potential use in managing other estrogen-related conditions, such as endometriosis and uterine fibroids. Its ability to modulate estrogen activity without fully antagonizing it offers a unique therapeutic profile that could be beneficial in these contexts.
Research is ongoing to explore other potential applications, including its use in reducing the risk of osteoporosis in postmenopausal women, given its selective estrogen receptor modulation properties. This could provide a dual benefit of cancer prevention and bone health maintenance.
Overall, afimoxifene represents a versatile compound with significant promise in the field of oncology and beyond, particularly in conditions influenced by estrogen activity.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White to off-white Solid |
| PURITY | 98.5-100 |
| LCMS | Consistent with structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | $137.05 |
+
-
|
| 0.025 | 10-20 days | $475.09 |
+
-
|
Afimoxifene
Afimoxifene is primarily used in the treatment of breast cancer, particularly in cases where the cancer is estrogen receptor-positive. It works by blocking the effects of estrogen on breast tissue, thereby inhibiting the growth of cancer cells that rely on estrogen to proliferate. This makes it a valuable option for both the prevention and treatment of breast cancer in postmenopausal women.
In addition to its anticancer properties, afimoxifene is also being investigated for its potential use in managing other estrogen-related conditions, such as endometriosis and uterine fibroids. Its ability to modulate estrogen activity without fully antagonizing it offers a unique therapeutic profile that could be beneficial in these contexts.
Research is ongoing to explore other potential applications, including its use in reducing the risk of osteoporosis in postmenopausal women, given its selective estrogen receptor modulation properties. This could provide a dual benefit of cancer prevention and bone health maintenance.
Overall, afimoxifene represents a versatile compound with significant promise in the field of oncology and beyond, particularly in conditions influenced by estrogen activity.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :